Chronic thrombotic microangiopathy in patients with a C3 gain of function protein

Sjoerd A.M.E.G. Timmermans1,3, Myrurgia H. Abdul-Hamid2 and Pieter van Paassen1,3, for the Limburg Renal Registry

1Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands, 2Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands and 3Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands

Correspondence to: Sjoerd A.M.E.G. Timmermans; E-mail: sjoerd.timmermans@mumc.nl

The syndromes of thrombotic microangiopathy (TMA) are rare and occur in patients with severe endothelial damage caused by various mechanisms [1]. The TMAs converge to a final common pathway, inducing microvascular thrombosis with platelet consumption, haemolysis and ischaemic damage, often affecting the kidneys. Endothelial damage can occur on the background of complement dysregulation as demonstrated in primary atypical haemolytic uraemic syndrome (aHUS) [2]. Most cases of primary aHUS present with acute TMA, while a small subset of patients present with chronic disease. Half the patients have rare variants in complement genes, encoding proteins that either regulate or activate complement and/or autoantibodies that inhibit complement regulation [1]. The genotype-phenotype correlation has clinical significance [3].

The aetiology and disease course of patients with chronic TMA remain poorly understood [3]. Smith-Jackson et al. [4] demonstrated that a gain of function change in C3 (i.e. p.D1115N) drives murine TMA with heavy proteinuria and chronic rather than acute TMA on kidney biopsy. The arginine to tryptophan substitution at amino acid 161 (i.e. p.R161W) in C3 has been identified in 8 (29%) of 28 patients with primary aHUS in the Limburg Renal Registry (Supplementary data, Figure S1) but not in 3 asymptomatic relatives; the variant’s minor allele frequency is <0.004% according to the Genome Aggregation Database and Exome Variant Server. C3 p.R161W results in a gain of function protein and has been linked to nephrotic-range proteinuria in more than half the patients [5], suggesting chronic damage to podocytes. In vivo and clinical observations therefore suggest that C3 gain of functional proteins may cause chronic TMA. Human morphological data, however, are not available.

Herein we evaluated this premise in seven patients with primary aHUS and C3 p.R161W included in the Limburg Renal Registry; one patient was excluded because no kidney tissue sections were available [6, 7]. No rare variants in CFH, CFI, CD46, CFB, THBD and DGKE were found using DNA sequencing (Supplementary data, Methods S1). CFH-H3 but not MCP_GGAAC was found in 3 (43%) patients. The homozygous deletion of CFHR1–CFHR3 was identified in one patient with no factor H autoantibodies. We therefore analysed the effect of C3 p.R161W in isolation. Our observations add to the understanding of the aetiology and disease course of patients with chronic TMA.

Baseline characteristics and outcome data have been depicted in Table 1, corroborating previous observations from the French cohort [5]. Patients presented with proteinuric kidney failure (mean serum creatinine 11.4 ± 5.4 mg/dL), either with nephrotic-range proteinuria (n = 4) or not. Normal platelet counts were found in 5 (71%) patients. C3 but not C4 levels were low in 6 (86%) patients. Kidney tissue sections showed double contour formation of the glomerular basement membrane, mesangiolysis and global foot process effacement (FPE), deletion of CD46, either with fibrin thrombi (n = 5) or not (Supplementary data, Figure S2). Moderate to severe interstitial fibrosis and tubular atrophy was present. These morphologic features thus suggest a smouldering rather than acute onset of disease. C3c but not immune complex deposits were found along segments of the glomerular basement membrane on immunofluorescence microscopy (n/N = 5/7; Supplementary data, Figure S2). Electron microscopy showed subendothelial electron-lucent material but not electron-dense deposits (n/N = 4/4; Supplementary data, Figure S2), excluding C3 glomerulopathy [8]; global FPE was found in three cases. Two patients presented with extrarenal manifestations. Patient 1 had seizures and left ventricular hypertrophy and Patient 5 had dilated cardiomyopathy at presentation.

Plasma exchange was started in five patients. Plasma exchange was associated with a complete clinical remission for at
least 3 years (i.e. chronic kidney disease Stage G1) in Patient 6. The other patients \( [n = 6 (86\%)] \) required dialysis and did not recover kidney function.

C3 p.R161W has been linked to a high risk of recurrent primary aHUS [3]. Six patients received a total of 10 kidney donors. Eight of 10 kidney donors were transplanted before eculizumab’s approval by the European Medicines Agency. Both other recipients (Patients 1 and 7) were transplanted with a transplantation protocol not using eculizumab prophylaxis [9]. Five (83\%) of six recipients developed TMA on allograft biopsy (episodes, \( n = 8 \)) with normal platelet counts in 5 (63\%) episodes (Supplementary data, Figure S3 and Table S1). Four episodes presented early, that is, <12 months after kidney transplantation, with microangiopathic haemolysis (\( n = 4 \)), low platelet counts (\( n = 2 \)) and acute TMA on donor kidney biopsy. Remarkably, four episodes presented ‘late’ with nephrotic-range proteinuria, normal platelet counts and morphologic features consistent with chronic TMA and C3c deposits (\( n/N = 3/4 \)), identical to native kidney biopsies; thrombosis was not found. Neither donor-specific alloantibodies nor C4d deposits were present along the peritubular capillaries and thus chronic transplant glomerulopathy was considered unlikely.

In all cases, including Patient 5 who had been treated with C5 inhibition, that is, eculizumab, graft loss developed. However, patient 5 presented with a creatinine of 5.5 mg/dL.

In the current study we demonstrated that primary aHUS linked to C3 p.R161W can present with chronic morphologic features of TMA, characterized by nephrotic-range proteinuria, normal platelet counts and a poor prognosis. The clinical and pathological observations on kidney biopsy are consistent with the murine data [4]. The affinity of C3 p.R161W for CD46 (i.e. membrane cofactor protein) is decreased [5, 10], identical to C3 p.D1115N [11]. This might explain the chronic morphologic features of TMA, identical to some patients with pathogenic variants in CD46 [12]. Also, cardiac and neurologic manifestations appeared prevalent in patients carrying C3 p.R161W [5].

C5 inhibition rescued affected mice despite the presence of chronic TMA [4]. In clinical practice, the use of therapeutic complement inhibition for the treatment of chronic TMA is debatable [3]. Patient 5, who relapsed ‘late’ after kidney transplantation, progressed to graft loss despite eculizumab. The donor kidney’s capacity to recover is limited as compared with native kidneys [13]. Early recognition is therefore of utmost importance. Proteinuria >1 g/day, although aspecific, may be a marker of smouldering disease after kidney transplantation.

In conclusion, C3 p.R161W and probably other C3 gain of function proteins may present with proteinuria related to chronic TMA, often with normal platelet counts. Recognition of these patients at an early stage of disease may improve the prognosis, and particularly kidney survival, in the era of therapeutic complement inhibition.

**SUPPLEMENTARY DATA**

Supplementary data are available at ndt online.

**ACKNOWLEDGEMENTS**

We gratefully thank the nephrologists affiliated with the Limburg Renal Registry. Furthermore, we appreciate Nele Bijnen and Henk van Rie (Maastricht University Medical Center) for the excellent technical assistance.

**AUTHORS’ CONTRIBUTIONS**

S.T. and P.P. contributed to the research idea and study design and analysed and interpreted the data. S.T. and M.A.H. S.A.M.E.G. Timmermans et al.
were involved in data acquisition. P.P. supervised the research. Each author contributed important intellectual content during manuscript drafting or revision, accepts personal accountability for his/her own contributions and agrees to ensure that questions pertaining to the accuracy or integrity of any portion of the work appropriately investigated and resolved.

CONFLICT OF INTEREST STATEMENT

The results presented in this article have not been published previously in whole or part.

REFERENCES

1. Fakhouri F, Zuber J, Fremeaux-Bacchi V et al. Haemolytic uraemic syndrome. Lancet 2017; 390: 681–696
2. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169–2181
3. Goodship TH, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2017; 91: 539–551
4. Smith-Jackson K, Yang Y, Denton H et al. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. J Clin Invest 2019; 129: 1061–1075
5. Roumenina LT, Frimat M, Miller EC et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 2012; 119: 4182–4191
6. van Paassen P, van Breda Vriesman PJ, van Rie H et al. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-the Limburg Renal Registry. Kidney Int 2004; 66: 909–913
7. Timmermans S, Abdul-Hamid MA, Potjewijd J et al. C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension. J Am Soc Nephrol 2018; 29: 2234–2243
8. Pickering MC, D’Agati VD, Nester CM et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079–1089
9. Duineveld C, Verhave JC, Berger SP et al. Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series. Am J Kidney Dis 2017; 70: 770–777
10. Schramm EC, Roumenina LT, Rybkine T et al. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood 2015; 125: 2359–2369
11. Fremeaux Bacchi V, Miller EC, Liszewski MK et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112: 4948–4952
12. Timmermans S, van Paassen P; on behalf of the Limburg Renal Registry. Mother and child reunion in “hypertensive” end-stage renal disease: will they complement each other? Nephron 2019; 142: 253–257
13. Siedlecki AM, Isbel N, Vande Walle J et al. Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep 2019; 4: 434–446

Received: 19.12.2019; Editorial decision: 19.2.2020